Business Wire

Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed to Treat Rare Diseases

Share

Veristat, a scientific-minded global clinical research organization (CRO), announced today that the Company supported clients in preparing marketing applications for eight therapies that received regulatory approval in 2022. The approvals from the US Food and Drug Administration (FDA) included one Biologics License Application (BLA), five New Drug Applications (NDAs), and one Supplemental New Drug Application (sNDA). One Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) was approved, and collectively most of the approvals were for therapies targeting a rare disease. Veristat’s success in preparing marketing applications that receive approval can be attributed to the ability of our integrated teams to navigate the complex regulatory submission process with the FDA and regulators around the world.

“At Veristat, we believe championing better health not only equates to finding cures for diseases but also improving patients’ abilities to more ably live with their disease,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “A key measure of our success is how effectively we advance the numerous possibilities for novel innovation to improve the quality and duration of human life. While it’s important to recognize our progress in advancing treatments through the development and approval process, there is more work to do, particularly in the area of rare diseases.”

According to the National Institutes of Health (NIH), there are approximately 7,000 rare diseases and only 5% of known rare diseases have one or more approved treatments. With February Rare Disease month, Veristat teams reaffirm their commitment to advancing rare disease research across several modalities that span gene therapies, cell therapies, and tissue engineering— including the first gene therapy approved in the Western world.

In the last three years, Veristat teams have:

  • Conducted 190+ rare disease projects for over 110 sponsors working on rare disease treatments
  • Prepared 30+ INDs and CTAs for rare disease therapies
  • Supported 55 Marketing Applications/Authorizations, of which 40% were for rare disease therapies
  • Celebrated the success of clients receiving more than 25 regulatory approvals for marketing applications prepared by Veristat teams, 75% of which were for rare disease therapies.

From regulatory pathway selection to patient recruitment and site access difficulties to the intricacies of data collection, a rare disease therapy requires an extraordinary amount of coordination and scientific understanding. Effective utilization of natural history studies and decentralized clinical trial deployment can be valuable.

“Rare disease research presents many challenges for trial design and regulatory strategy,” stated John Balser, Ph.D., Veristat Founder, President, and Chief Statistical Officer. “Small population sizes, uncertainty in clinical endpoint requirements, and an often limited understanding of the physiological basis of the disease can make for a difficult path forward. Over 30% of Veristat’s work is in rare diseases. The knowledge we have amassed has been game-changing for sponsors. Our creative approaches have helped them overcome daunting evidentiary and regulatory hurdles to gain swift and successful therapy approval.”

About Veristat

Veristat, a scientific-minded global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval and commercialization. With more than 28 years of experience in clinical trial planning and execution, Veristat is equipped to support any development program.

Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. Every day, we apply this knowledge base to solve any program’s clinical, regulatory, statistical, data, or operational challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving patients’ lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lauren L. Brennan, Vice President of Marketing, Veristat
media@veristat.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Ministry of Education and Science of Ukraine and Palantir Partner to Create Safe Conditions for In-Person Education in Schools28.3.2024 12:00:00 EET | Press release

The Ministry of Education and Science, along with Palantir (NYSE:PLTR), a leading provider of AI systems, have signed an agreement. The main goal is to facilitate qualitative transformations in the field of education and ensure the maximum number of children have access to safe in-person learning. The agreement, initially for 12 months, will support the Government’s official School Offline initiative which aims to provide 300,000 more Ukrainian pupils with safe access to a school. New software tooling will enable: Funding allocated for school bomb shelters to be targeted where it will deliver the greatest benefit for children and young people of a school age. Every school to receive a risk rating according to a methodology recently adopted in law as a Cabinet of Ministers decree, in order to help identify targeted measures that will improve the safety of a school. The rating will take into account factors such as historic shelling in the area, presence of a bomb shelter, safety of acce

Guidewire Jasper Release Boosts Commercial Lines Agility for P&C Insurers and Strengthens Functionality Across Entire Product Portfolio28.3.2024 10:05:00 EET | Press release

Guidewire (NYSE: GWRE) announces Jasper, its latest release, which boosts commercial lines agility for P&C insurers with support for layered coinsurance, schedule import, and a new U.S. Bureau Content Solution.* Additionally, expanded HazardHub data for Canada gives insurers deeper property risk insights for underwriting precision. Jasper release will be generally available on April 5, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328607054/en/ “Commercial lines insurers face both risk and opportunity. On the one hand, there are economic fluctuations, including inflation, geopolitical complexities, capital limitations, and environmental challenges. On the other hand, the protection gap creates growth opportunities for insurers that innovate to stay ahead of the evolving risk landscape,” said Eugene Lee, senior vice president and general manager, InsuranceSuite, Guidewire. For P&C insurers seeking to improve commerc

Surge announces closing of a €7.5 million fundraising round to decrypt the immune system and transform precision medicine28.3.2024 10:00:00 EET | Press release

Surge has just closed its second round of funding, raising €7.5 million. The round was led by Eurazeo with the participation of Kima, Teampact, and MH Innov’, as well as the support of historical funds Boutique Venture, HCVC, and 50 Partners Santé. The fundraising is complemented by grants from BPI, including support for deep tech development and the Future Investment Program, of which Surge was a laureate. This second round of funding, marked by the entry of strategic investors, reflects Surge's accelerated development and the beginning of the commercial expansion phase. This funding will enable the opening of SurgeLab™, a premier laboratory dedicated to the discovery of immune biomarkers, and the finalization of PreCyte®'s industrialization. It will also support the refinement of its cutting-edge AI algorithms. "Building on solid scientific and technical fundamentals, Surge has already demonstrated the relevance of its biomarker discovery platform to address concrete clinical needs a

EIG’s MidOcean Energy Completes Acquisition of Tokyo Gas’ Interests in Portfolio of Australian Integrated LNG Projects28.3.2024 10:00:00 EET | Press release

MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, a leading institutional investor in the global energy and infrastructure sectors, today announced the completion of its previously announced agreement to acquire Tokyo Gas Co., Ltd’s (“Tokyo Gas”) interests in a portfolio of Australian integrated LNG projects. The acquisition includes Tokyo Gas’ interests in the Gorgon LNG, Pluto LNG and Queensland Curtis LNG projects. The portfolio benefits from experienced operators, including Chevron, Woodside and Shell, and spans the LNG value chain from upstream operations to midstream, liquefaction and sales. As part of the transaction, MidOcean will open an office in Perth, Australia, to support and oversee the projects. R. Blair Thomas, EIG’s Chairman and CEO said, “We are strong believers in the role of LNG as a key enabler of the energy transition and have formed MidOcean to provide partners and investors differentiated exposure to the asset class.

Midea Group Breaks Revenue and Profit Records with RMB 373.7 Billion in 202328.3.2024 08:48:00 EET | Press release

Midea Group, the world's largest home appliance supplier, has reported impressive growth and record profits in its 2023 annual report. The company achieved a total revenue of RMB 373.7 billion, representing a year-on-year increase of 8.10%. Concurrently, the net profit attributable to shareholders reached RMB 33.7 billion, a year-on-year increase of 14.10%, marking the largest growth since 2019. The company's success is attributed to its "Global Impact" strategy, which has resulted in overseas sales accounting for over 40% of its total sales for several years. Midea's products have been exported to over 200 countries and regions worldwide, and it is continuously expanding its overseas manufacturing layout, promoting the construction of manufacturing bases in Indonesia, India, Thailand, Brazil, Mexico, Italy, Egypt, and other countries. Midea's new energy and industrial technology are co-builders of digital transformation and green sustainable development in the global industrial field,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye